All these are expected to delay the facility's clearance for manufacturing products for the US market. On the other hand, Glenmark in its earnings conference call cited that the company would face pricing pressure in the US market, especially for its asthma generic drug Advair. The company is also planning to spin-off its innovative business to unlock shareholder value. The stock of Sun Pharma was being punished despite stellar result. However, the company has been in news for corporate governance issues. Reacting to these developments, at 11:37 hours, the Nifty Pharma index was at 8,558.65, down 362.25 points or 4.06 per cent dragged mainly by Dr. Reddy's Lab at Rs. 2,464.80, down by Rs. 202.45 or 7.59 per cent, while Glenmark was at Rs. 572.40, down by Rs. 36.80 or 6.04 per cent. Other pharma stocks including Sun Pharma and Divis Labs were down 4 per cent, while rest of the index components PEL, Biocon, Aurobindo, Lupin, Cadila, Cipla were down between 3 to 2 per cent, on Friday.